Clinical trial
Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial
NCT04895020 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Evaluating the Immunogenicity and Safety of 9-valent Human Papillomavirus(Type6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine in Chinese Females Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomised Clinical Trial
- Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- May 28, 2021
- Completion date
- May 31, 2026
- Enrollment
- 1,200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
ais, cervical cancer, cin 3, cin1, cin2, genital wart, hpv infections, vaginal cancer, vain1, vain2, vain3, vin 1, vin 2, vin 3, vulvar cancer